JP2019529520A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529520A5
JP2019529520A5 JP2019518506A JP2019518506A JP2019529520A5 JP 2019529520 A5 JP2019529520 A5 JP 2019529520A5 JP 2019518506 A JP2019518506 A JP 2019518506A JP 2019518506 A JP2019518506 A JP 2019518506A JP 2019529520 A5 JP2019529520 A5 JP 2019529520A5
Authority
JP
Japan
Prior art keywords
biliary tract
composition according
composition
tract cancer
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019518506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/055559 external-priority patent/WO2018067943A1/en
Publication of JP2019529520A publication Critical patent/JP2019529520A/ja
Publication of JP2019529520A5 publication Critical patent/JP2019529520A5/ja
Pending legal-status Critical Current

Links

JP2019518506A 2016-10-07 2017-10-06 胆道がんを処置する方法 Pending JP2019529520A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662405706P 2016-10-07 2016-10-07
US62/405,706 2016-10-07
PCT/US2017/055559 WO2018067943A1 (en) 2016-10-07 2017-10-06 Methods of treating biliary tract cancer

Publications (2)

Publication Number Publication Date
JP2019529520A JP2019529520A (ja) 2019-10-17
JP2019529520A5 true JP2019529520A5 (enExample) 2020-11-12

Family

ID=61831977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019518506A Pending JP2019529520A (ja) 2016-10-07 2017-10-06 胆道がんを処置する方法

Country Status (9)

Country Link
US (1) US20200129469A1 (enExample)
EP (1) EP3522887A4 (enExample)
JP (1) JP2019529520A (enExample)
KR (1) KR20190066033A (enExample)
AU (1) AU2017340913A1 (enExample)
BR (1) BR112019006329A2 (enExample)
CA (1) CA3039582A1 (enExample)
MX (1) MX2019003694A (enExample)
WO (1) WO2018067943A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
JP6987644B2 (ja) 2015-06-29 2022-01-05 アブラクシス バイオサイエンス, エルエルシー 類上皮細胞腫瘍を処置する方法
RU2020134124A (ru) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
WO2021086946A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
KR20230124947A (ko) * 2020-12-22 2023-08-28 사이토테릭스 인코포레이티드 담즙 전달 방법, 이에 사용하기 위한 조성물 및 키트

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2552438T3 (pl) * 2010-03-26 2016-12-30 Sposoby leczenia raka wątrobowokomórkowego
EP3056201A1 (en) * 2010-06-07 2016-08-17 Abraxis BioScience, LLC Combination therapy methods for treating proliferative diseases
WO2012151562A1 (en) * 2011-05-04 2012-11-08 Intellikine, Llc Combination pharmaceutical compositions and uses thereof
US20140199404A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US20160101128A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors

Similar Documents

Publication Publication Date Title
JP2019529520A5 (enExample)
JP2013523656A5 (enExample)
JP2016513097A5 (enExample)
JP2013503174A5 (enExample)
Rowinsky et al. Paclitaxel (taxol)
JP2016513075A5 (enExample)
JP2013527233A5 (enExample)
JP2010509331A5 (enExample)
Markman et al. Paclitaxel in cancer therapy
RU2012156275A (ru) Способ и лечение рака поджелудочной железы
JP2020012005A (ja) 治療薬の組み合わせおよび投与の様式ならびに併用療法
RU2009121568A (ru) Комбинации и способы введения терапевтических агентов и комбинированная терапия
HRP20160609T1 (hr) Postupci liječenja hepatocelularnog karcinoma
RU2017104909A (ru) Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
JP2019521180A5 (enExample)
HRP20160551T1 (hr) Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora
JP2010529025A5 (enExample)
JP2016506908A5 (enExample)
JP2010523696A5 (enExample)
JP2016536352A5 (enExample)
JP2020523354A5 (enExample)
JP2016515586A5 (enExample)
JP2020523356A5 (enExample)
JP2017527582A5 (enExample)
JP2019506392A5 (enExample)